Alamar Biosciences Appoints Director Robert Ragusa

What Happened
Alamar Biosciences, Inc. (ALMR) filed an 8‑K on Sept 1, 2026 reporting that its board appointed Robert Ragusa as a Class I director, effective September 1, 2026. The appointment was made on August 28, 2026, and Ragusa’s initial term will expire at the Company’s 2027 Annual Meeting of Stockholders.

Key Details

• Appointment date filed: 8‑K dated Sept 1, 2026; Board action taken August 28, 2026, effective Sept 1, 2026.
• Director class/term: Named a Class I Director; initial term ends at 2027 Annual Meeting.
• Committee assignments: Joined the Audit Committee, Compensation Committee, and Nominating & Corporate Governance Committee.
• Compensation & agreements: Will be paid under the Company’s Non‑Employee Director Compensation Policy (as described in the April 17, 2026 prospectus) and will enter the Company’s standard indemnification agreement.
• No conflicts disclosed: Company reported no arrangements or understandings that led to his selection and no related‑person transactions required to be disclosed under Item 404(a).

Why It Matters
Board changes affect corporate oversight and governance. Adding a director who will serve on the Audit Committee is material for investors because that committee oversees financial reporting and controls. The filing indicates Ragusa’s pay follows previously disclosed policy and that there are no related‑person transactions, suggesting this is a routine governance appointment rather than a compensatory or affiliated‑party arrangement.